# The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.

> **NCT06029829** · PHASE2 · UNKNOWN · sponsor: **Xin-Hua Xu** · enrollment: 60 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT06029829
- **Lead sponsor:** Xin-Hua Xu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-12
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06029829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06029829, "The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06029829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*